Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm

Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Regenxbio, Inc. (NASDAQ: RGNX ) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Regenxbio, Inc. provided investors with false and/or misleading information regarding the efficacy and safety of its trial study for RGX-111, a one-time gene therapy for the treatment of Hurler Syndrome, including positive assertions of RGX-111's future trial success based on continuing positive biomarker and safety data from the ongoing PhaseI/II study. If you currently own RGNX and purchased prior to February 9, 2022 please contact Sophia Anne Silayan by email at [email protected] or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.